

Stephen V Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4718671/publications.pdf>

Version: 2024-02-01

192
papers

9,239
citations

136950

32
h-index

45317

90
g-index

194
all docs

194
docs citations

194
times ranked

12913
citing authors

#	ARTICLE	IF	CITATIONS
1	Index Admission and Thirty-Day Readmission Outcomes of Patients With Cancer Presenting With STEMI. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 121-128.	0.8	3
2	The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 52-59.	2.6	11
3	Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 111-116.	2.8	1
4	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
5	Evolving role of immunotherapy in small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 868-874.	9.6	19
6	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. <i>Investigational New Drugs</i> , 2022, 40, 782-788.	2.6	5
7	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	1.1	15
8	Genomic analysis of clear cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5548-5548.	1.6	0
9	Reversion mutations in <i>BRCA1</i> or <i>BRCA2</i> genes: Resistant mechanism(s) in patients treated with platinum-based agents or poly (ADP-ribose) polymerase(PARP) inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3132.	1.6	0
10	A pancancer analysis of impact of <i>MDM2/MDM4</i> on immune checkpoint blockade (ICB).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2630-2630.	1.6	2
11	Pan-cancer association between increased iron utilization and poor prognosis highlights potential of transferrin receptor-targeting therapies in multiple tumor types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3120.	1.6	0
12	Abstract 5699: Overexpression of KMT2A is associated with worse prognosis and specific immune signatures in patients with TP53-mutated hepatocellular carcinomas. <i>Cancer Research</i> , 2022, 82, 5699-5699.	0.9	0
13	Efficacy of afatinib in patients with advanced/metastatic solid tumors harboring <i>NRG1</i> gene fusions: A novel, prospective real-world outcomes study based on single-patient protocol data.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3180-TPS3180.	1.6	2
14	Acquired EGFR-resistant mutations in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9113-9113.	1.6	1
15	Molecular characterization of NF1-mutated NSCLC and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9086-9086.	1.6	1
16	Treatment patterns and outcomes in <i>ALK</i> or <i>ROS1</i> altered NSCLC: An ATOMIC Registry Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9077-9077.	1.6	0
17	Characterization of <i>MET</i> exon 14 skipping alterations (<i>MET</i> ex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9122-9122.	1.6	0
18	Analysis of <i>MET</i> exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9119-9119.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, e21149-e21149.	1.6	0
20	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology, 2022, 40, LBA8507-LBA8507.	1.6	46
21	Therapeutic Potential of Afatinib in <i>NRG1</i> Fusion-Driven Solid Tumors: A Case Series. Oncologist, 2021, 26, 7-16.	3.7	31
22	Identification of Novel <i>CDH1-NRG2</i> ± and <i>F11R-NRG2</i> ± Fusions in NSCLC Plus Additional Novel <i>NRG2</i> ± Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clinical and Research Reports, 2021, 2, 100132.	1.1	7
23	Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta Oncologica, 2021, 60, 649-652.	1.8	2
24	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. , 2021, 9, e001999.		26
25	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 2021, 39, 619-630.	1.6	317
26	Immunotherapy in lung cancer. Journal of Surgical Oncology, 2021, 123, 718-729.	1.7	7
27	Effect of prior therapy on tumor mutational burden in NSCLC. Translational Lung Cancer Research, 2021, 10, 1231-1238.	2.8	2
28	Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. Cancers, 2021, 13, 1152.	3.7	11
29	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	1.6	74
30	Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. Oncologist, 2021, 26, 694-700.	3.7	5
31	Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.. Journal of Clinical Oncology, 2021, 39, 11036-11036.	1.6	0
32	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer, 2021, 22, 201-209.	2.6	24
33	Divergent <i>RET</i> - and <i>BRAF</i> -Mediated Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC: A Case Report. JCO Precision Oncology, 2021, 5, 939-942.	3.0	6
34	Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.. Journal of Clinical Oncology, 2021, 39, 8535-8535.	1.6	6
35	Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, e20533-e20533.	1.6	1
36	Safety and efficacy of pralsetinib in patients with advanced <i>RET</i> fusion-positive non-small cell lung cancer: Update from the ARROW trial.. Journal of Clinical Oncology, 2021, 39, 9089-9089.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.. Journal of Clinical Oncology, 2021, 39, e21000-e21000.	1.6	0
38	Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types.. Journal of Clinical Oncology, 2021, 39, 3091-3091.	1.6	0
39	Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.. Journal of Clinical Oncology, 2021, 39, 8508-8508.	1.6	4
40	Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.. Journal of Clinical Oncology, 2021, 39, 2552-2552.	1.6	8
41	EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report. JTO Clinical and Research Reports, 2021, 2, 100179.	1.1	3
42	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. Clinical Lung Cancer, 2021, 22, 483-499.	2.6	11
43	Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer. Clinics and Practice, 2021, 11, 441-454.	1.4	2
44	NRG1 fusions: Biology to therapy. Lung Cancer, 2021, 158, 25-28.	2.0	6
45	A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 728155.	2.8	9
46	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 2577-2584.	4.1	66
47	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	1.6	32
48	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clinical Cancer Research, 2021, 27, 1463-1475.	7.0	52
49	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology, 2021, 5, 1802-1812.	3.0	9
50	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget, 2021, 12, 2449-2458.	1.8	5
51	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
52	Drugs in development for small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6298-6307.	1.4	14
53	Novel ALK mutation with durable response to brigatinib—a case report. Translational Lung Cancer Research, 2020, 9, 2145-2148.	2.8	2
54	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 815-827.	2.3	12

#	ARTICLE	IF	CITATIONS
55	Tracking the tail. , 2020, 8, e000971.		3
56	Oral Chemotherapy for Treatment of Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 793.	2.8	13
57	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
58	Small Cell Lung Cancer: Advances in Diagnosis and Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 435-446.	2.1	10
59	Phase I study of the ¹⁷⁷ Lu-DOTA ⁰ -Tyr ³ -Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. , 2020, 8, e000980.		44
60	Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 20.	4.0	11
61	The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2020, 21, e539-e543.	2.6	19
62	Chemo-immunotherapy as first-line treatment for small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098036.	3.2	8
63	Characterization of NRG1 gene fusion events in solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3113-3113.	1.6	5
64	A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3654-TPS3654.	1.6	10
65	Abstract 15368: Index Admission and Thirty-day Readmission Outcomes of Cancer Patients Presenting With Stemi. <i>Circulation</i> , 2020, 142, .	1.6	0
66	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 180-193.	5.9	35
67	First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. <i>Annals of Oncology</i> , 2019, 30, 1852-1855.	1.2	13
68	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. <i>Annals of Oncology</i> , 2019, 30, 1686-1688.	1.2	20
69	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	1.1	69
70	Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential. <i>Advances in Therapy</i> , 2019, 36, 1826-1832.	2.9	21
71	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	7.0	30
72	Detection of NRG1 Gene Fusions in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4966-4972.	7.0	145

#	ARTICLE	IF	CITATIONS
73	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019, 14, 596-605.	1.1	56
74	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
75	Linear IgA Disease of the Gingiva Following Nivolumab Therapy. <i>Journal of Immunotherapy</i> , 2019, 42, 345-347.	2.4	6
76	A Phase I/IIb Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
77	Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections. , 2019, , .		1
78	Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2587-2587.	1.6	5
79	Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2619-2619.	1.6	3
80	Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2627-2627.	1.6	9
81	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9008-9008.	1.6	75
82	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9081-9081.	1.6	11
83	Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9083-9083.	1.6	8
84	DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9100-9100.	1.6	8
85	Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors.. <i>Journal of Global Oncology</i> , 2019, 5, 110-110.	0.5	5
86	Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?. <i>Annals of Translational Medicine</i> , 2019, 7, S76-S76.	1.7	5
87	Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e14272-e14272.	1.6	0
88	Tumor mutational burden (TMB) profile of <i>K-RAS/TP-53</i> co-mutation in metastatic non-small cell lung cancer (m-NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2626-2626.	1.6	0
89	Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). , 2019, , .		3
90	Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). , 2019, , .		8

#	ARTICLE	IF	CITATIONS
91	NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry. , 2019, , .		0
92	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1083-1088.	1.3	145
93	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncology, The, 2018, 19, 347-355.	10.7	290
94	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2018, 81, 587-596.	2.3	66
95	Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines and Immunotherapeutics, 2018, 14, 269-276.	3.3	41
96	Combinatorial Immunotherapy and Chemotherapy. Current Cancer Research, 2018, , 199-218.	0.2	4
97	MA02.01 ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2018, 13, S357-S358.	1.1	0
98	Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology, 2018, 29, ix175.	1.2	22
99	Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology, 2018, 2, 1-7.	3.0	32
100	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	3.0	8
101	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2220-2229.	27.0	2,228
102	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. European Journal of Cancer, 2018, 101, 114-122.	2.8	45
103	A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. Frontiers in Oncology, 2018, 8, 64.	2.8	13
104	A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 723-732.	2.3	5
105	Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). Cancer Research, 2018, 78, LB-339-LB-339.	0.9	34
106	Incidence of <i>Neuregulin1</i> (<i>NRG1</i>) gene fusions across tumor types.. Journal of Clinical Oncology, 2018, 36, 12084-12084.	1.6	4
107	Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, e15074-e15074.	1.6	9
108	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e21231-e21231.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, TPS8589-TPS8589.	1.6	3
110	Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, TPS9113-TPS9113.	1.6	1
111	Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.. Journal of Clinical Oncology, 2018, 36, 521-521.	1.6	27
112	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 169-169.	1.6	5
113	Racial Disparities in the Molecular Landscape of Cancer. Anticancer Research, 2018, 38, 2235-2240.	1.1	32
114	A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR1 agonist to treat select solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS2617-TPS2617.	1.6	0
115	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist, 2017, 22, 152-157.	3.7	9
116	P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology, 2017, 12, S1299.	1.1	1
117	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
118	A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC. Annals of Oncology, 2017, 28, v612.	1.2	7
119	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 742-749.	1.9	21
120	Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion. JCO Precision Oncology, 2017, 1, 1-5.	3.0	11
121	Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Resistant Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Journal of Clinical Oncology, 2017, 35, 3315-3321.	1.6	106
122	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology, 2017, 35, 1542-1549.	1.6	527
123	Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Research, 2017, 77, CT060-CT060.	0.9	13
124	Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study.. Journal of Clinical Oncology, 2017, 35, 8573-8573.	1.6	14
125	Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.. Journal of Clinical Oncology, 2017, 35, 9092-9092.	1.6	18
126	Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133).. Journal of Clinical Oncology, 2017, 35, TPS8584-TPS8584.	1.6	2

#	ARTICLE	IF	CITATIONS
127	A phase II trial of zoletarelin doxorubicin in castration- and taxane-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 210-210.	1.6	1
128	ctDNA detection of EGFR mutations in NSCLC patients using TargetSelector.. Journal of Clinical Oncology, 2017, 35, e23037-e23037.	1.6	0
129	Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC).. Journal of Clinical Oncology, 2017, 35, e17580-e17580.	1.6	2
130	A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, e20622-e20622.	1.6	1
131	PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology, 2016, 11, S305-S306.	1.1	6
132	What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Annals of Oncology, 2016, 27, 920-926.	1.2	261
133	First-line immunotherapy in lung cancer â€” taking the first step. Nature Reviews Clinical Oncology, 2016, 13, 595-596.	27.6	5
134	Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. Journal of Neuroimmunology, 2016, 299, 70-78.	2.3	7
135	Rociletinib-associated cataracts in EGFR-mutant NSCLC. Annals of Oncology, 2016, 27, vi428.	1.2	0
136	Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs). Annals of Oncology, 2016, 27, vi138.	1.2	3
137	Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. Cancer Research, 2016, 76, CT007-CT007.	0.9	17
138	A phase 1b dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 101-101.	1.6	64
139	A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).. Journal of Clinical Oncology, 2016, 34, 2589-2589.	1.6	2
140	Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2016, 34, 6011-6011.	1.6	11
141	Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.. Journal of Clinical Oncology, 2016, 34, 6017-6017.	1.6	7
142	A phase II study of pembrolizumab in patients with recurrent thymic carcinoma.. Journal of Clinical Oncology, 2016, 34, 8517-8517.	1.6	14
143	Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2016, 34, 8564-8564.	1.6	6
144	Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.. Journal of Clinical Oncology, 2016, 34, 9001-9001.	1.6	23

#	ARTICLE	IF	CITATIONS
145	A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).. Journal of Clinical Oncology, 2016, 34, TPS6105-TPS6105.	1.6	4
146	Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.. Journal of Clinical Oncology, 2016, 34, TPS9100-TPS9100.	1.6	8
147	Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.. Journal of Clinical Oncology, 2016, 34, e23158-e23158.	1.6	0
148	Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients.. Journal of Clinical Oncology, 2016, 34, 6558-6558.	1.6	0
149	Incidence of ALK, cKIT, cMET, EGFR, PD1/PD-L1, and JAK3 alterations in 170 malignant pleural mesotheliomas (MPM) and 102 peritoneal mesotheliomas.. Journal of Clinical Oncology, 2016, 34, e20076-e20076.	1.6	0
150	Atezolizumab in lung cancerâ€”appreciating the differences. Translational Cancer Research, 2016, 5, S470-S473.	1.0	0
151	2539 A phase II trial of AEZS-108 in castration and taxane resistant prostate cancer. European Journal of Cancer, 2015, 51, S488.	2.8	0
152	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1670-1674.	1.1	197
153	29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. European Journal of Cancer, 2015, 51, S724-S725.	2.8	12
154	MP37-06 TARGETED SEQUENCING OF PROSTATE CANCER CIRCULATING TUMOR CELLS AND COMPARISON WITH MATCHED CELL FREE DNA AND PROSTATE TUMORS. Journal of Urology, 2015, 193, .	0.4	0
155	Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 536-540.	0.4	28
156	Refining the treatment of NSCLC according to histological and molecular subtypes. Nature Reviews Clinical Oncology, 2015, 12, 511-526.	27.6	247
157	Thermoresponsive release of viable microfiltrated Circulating Tumor Cells (CTCs) for precision medicine applications. Lab on A Chip, 2015, 15, 4277-4282.	6.0	22
158	Effects of luteinizing hormone receptor signaling in prostate cancer cells. Prostate, 2015, 75, 141-150.	2.3	14
159	STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology, 2015, 33, 2596-2596.	1.6	22
160	Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8030-8030.	1.6	32
161	A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.. Journal of Clinical Oncology, 2015, 33, e19033-e19033.	1.6	0
162	Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
163	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6277-6283.	7.0	39
164	Refining standard practice and admitting uncertainty. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 69-70.	27.6	6
165	Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2014, 50, 2747-2751.	2.8	6
166	Emerging protein kinase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 51-65.	2.4	22
167	Epigenetic Therapy in Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 135.	2.8	29
168	Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinoma. <i>Head and Neck</i> , 2013, 35, E343-E345.	2.0	9
169	Breast metastasis from nasopharyngeal carcinoma: A case report and review of the literature. <i>Oncology Letters</i> , 2013, 5, 1859-1861.	1.8	6
170	Thymomas: The Need for Prospective Studies. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1230-1231.	1.1	1
171	Circulating Tumor Cells as Biomarkers. , 2013, , 297-318.		0
172	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
173	Abstract 4356: EphB4 as a novel therapeutic target for head-neck SCC.. , 2013, , .		0
174	Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors.. , 2013, , .		0
175	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , 2012, 9, 065004.	1.8	8
176	A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 574-578.	1.1	32
177	Metastatic pancreatic cancer during pregnancy presenting as pseudo-Meigsâ€™ syndrome. <i>Gynecological Surgery</i> , 2012, 9, 323-325.	0.9	2
178	Metastatic Clear Cell Adenocarcinoma of the Urethra in a Male Patient: Report of a Case. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 47-49.	1.9	7
179	Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 607-609.	1.5	4
180	Ductal carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in current management. <i>Journal of Surgical Oncology</i> , 2012, 105, 212-220.	1.7	15

#	ARTICLE	IF	CITATIONS
181	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, 60-60.	1.6	0
182	Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opinion on Investigational Drugs, 2011, 20, 769-778.	4.1	27
183	7043 POSTER A Phase I/II Trial of AN-152 in Castration- and Taxane-Resistant Prostate Cancer. European Journal of Cancer, 2011, 47, S497.	2.8	0
184	Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate, 2011, 71, 892-898.	2.3	26
185	Therapy-Related Acute Myeloid Leukemia following Treatment with Trabectedin for Ewing's Sarcoma. Acta Haematologica, 2011, 126, 76-78.	1.4	2
186	Prostate cancer outcomes and polymorphism in LHRH and LH receptors and SHBG.. Journal of Clinical Oncology, 2011, 29, 5-5.	1.6	0
187	LH-receptor polymorphisms and response to androgen deprivation therapy in prostate cancer.. Journal of Clinical Oncology, 2011, 29, 4597-4597.	1.6	0
188	Neoadjuvant therapy for breast cancer. Journal of Surgical Oncology, 2010, 101, 283-291.	1.7	116
189	Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists. Clinical Cancer Research, 2010, 16, 4675-4680.	7.0	49
190	Rac1 promotes intestinal epithelial restitution by increasing Ca ²⁺ influx through interaction with phospholipase C- β 1 after wounding. American Journal of Physiology - Cell Physiology, 2008, 295, C1499-C1509.	4.6	46
191	Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. American Journal of Hematology, 2007, 82, 1071-1075.	4.1	15
192	α 4 integrin is expressed in a subset of cranial neural crest cells and in epicardial progenitor cells during early mouse development. Mechanisms of Development, 2001, 100, 99-103.	1.7	42